由蛋白质酶抑制剂积累的过度激活诱导的cytidine deaminase在激活的B细胞样扩散大B细胞淋巴瘤中拯救了异常的类切换
Zhuangwei Lv1,2, Chen Xu3, Zhenzhen Wang4,5
1Department of Laboratory Medicine, Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China.
蛋白质酶抑制剂MG132通过恢复异常的B细胞抗体类切换重组 (CSR) 来阻止淋巴瘤的生长. MG132增加了激活诱导的细胞氨酸脱氨酶 (AID) 水平,纠正激活B细胞样扩散大B细胞淋巴瘤 (ABC-DLBCL) 中的CSR缺陷.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物化学 生物化学
背景情况:
- 激活诱导的cytidine deaminase (AID) 对于通过体质突变和类交换重组 (CSR) 的抗体多样化至关重要.
- 由AID调解的异常免疫球蛋白CSR与激活B细胞样扩散大B细胞淋巴瘤 (ABC-DLBCL) 有关.
研究的目的:
- 为了研究MG132的治疗潜力,一个蛋白酶和calpain抑制剂,在ABC-DLBCL.
- 阐明MG132影响AID积累和ABC-DLBCL中的CSR的机制.
主要方法:
- 用MG132治疗ABC-DLBCL细胞系和异种移植瘤.
- 评估细胞死亡,瘤生长抑制和AID蛋白水平.
- 在体外和体内对免疫球蛋白类交换重组 (CSR) 的分析.
主要成果:
- MG132诱导了ABC-DLBCL细胞的显著细胞死亡,并在异种移植模型中抑制了瘤生长.
- 通过抑制其蛋白质体降解,MG132治疗导致了AID的积累.
- MG132在ABC-DLBCL细胞和小鼠中恢复了功能障碍的CSR,促进了IgM到IgG1,IgG3和IgE切换.
结论:
- MG132通过恢复正常的CSR来证明对ABC-DLBCL的抗淋巴瘤作用.
- 像MG132这样的蛋白质酶抑制剂通过向AID介导的CSR来代表ABC-DLBCL的潜在治疗策略.
更多相关视频
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
11:06Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
Published on: September 20, 2017
相关概念视频
The Intrinsic Apoptotic Pathway
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity
Abnormal Proliferation
